Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
September 2004
Features
Health Care and Law
Advocates Pursue a Public Registry for All Clinical Trials
Dr. Field discusses the benefits and drawbacks of disclosing clinical trial results to the public.
Robert I. Field, JD, MPH, PhD
Partnering for Quality and Patient Safety: A Provider/Payer Collaborative
The authors present an illustration of an innovative Hospital Quality Incentive Payment System for improved patient care.
Mark Baumel, MD, MS, Jeff Danilo, Linda Hart, Steve Brown, MD, Timothy Zeddies, PhD, Kathleen Clark, and Joseph C. Gallo, Jr.
Recent Controversies in Consumer Lawsuits: When Medical Devices Fail
Dr. Goldenberg reviews the role of the FDA, safety issues regarding new medical devices, and some of the possible reasons for their failure and recall.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
Comparative Effects of Available Thiazolidinediones: A Review of the Literature
Dr. Yates discusses the use of two agents, pioglitazone and rosiglitazone, in the treatment of patients with type-2 diabetes after the removal of troglitazone from the market.
Scott W. Yates, MD, MBA
Departments
Editorial
Clinical Trials and Tribulations
David Nash, MD, MBA, details some of the challenges involved in developing the contract language of clinical trials.
David Nash, MD, MBA
Medication Errors
Oral Liquid Medications: More Vulnerable to Errors Than Previously Recognized
Matthew Grissinger, RPh, FASCP, discusses ways to prevent errors involving liquid medications.
Matthew Grissinger, RPh, FASCP
Letters to the Editor
Prescription: Washington
Surf’s Up! New Electronic Health Records Initiative Creates Waves
Stephen Barlas discusses a large-scale effort to accelerate the arrival of electronic health records for patients in the U.S.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Risperdal Consta™: The First Long-Acting Atypical Antipsychotic Agent
The authors review risperidone (Risperdal Consta™), the first long-acting atypical antipsychotic agent.
Suzanne Thompson, PharmD, and Jose A. Rey, PharmD
